What to Expect from Agios Pharmaceuticals' Upcoming Earnings
What to Expect from Agios Pharmaceuticals' Upcoming Earnings
Agios Pharmaceuticals (NASDAQ: AGIO) is gearing up to unveil its quarterly earnings report soon. Investors are eagerly awaiting this announcement, looking for key insights that could shape their investment strategy.
Analysts project Agios to report earnings per share (EPS) of $-1.01. This figure sets the stage for what could be a revealing earnings call. Investors will not only focus on the report itself but also hope for encouraging guidance moving forward, which is often a major determinant of market reactions.
Review of Previous Earnings Performance
In the previous quarter, Agios Pharmaceuticals fell short of EPS expectations by $0.10. This disappointment was followed by a 1.21% dip in share price the next day, highlighting how critical earnings reports can be to market perceptions.
Looking back at prior earnings, here’s a glimpse into Agios’ recent performance along with the aftermath on share price:
Quarter EPS Estimates & Actuals (Q2 2024 to Q3 2023)
EPS Estimates:
- Q2 2024: -1.59
- Q1 2024: -1.65
- Q4 2023: -1.65
- Q3 2023: -1.70
EPS Actuals:
- Q2 2024: -1.69
- Q1 2024: -1.45
- Q4 2023: -1.72
- Q3 2023: -1.64
Price Change:
- Q2 2024: -1.0%
- Q1 2024: -0.0%
- Q4 2023: -1.0%
- Q3 2023: +7.0%
Insights from Analysts on Agios Pharmaceuticals
For those investing in Agios, understanding the general sentiment within the market is crucial. Recent analyst reports reveal that the consensus rating for Agios Pharmaceuticals is 'Outperform', with an average one-year price target set at $53.6. This indicates a potential upside of about 14.46%, suggesting optimism about the company's future performance.
Comparative Ratings Within the Industry
When analyzing the competitor landscape, it's important to examine how Agios stacks up against its peers such as Veracyte, Catalyst Pharmaceuticals, and Geron. Here’s a summary of analyst ratings and their respective price targets:
- Veracyte: Analysts recommend a 'Buy' with a one-year price target of $36.17, reflecting a potential downside of 22.76%.
- Catalyst Pharmaceuticals: Analysts also rate it as a 'Buy', with a price target of $30.33, indicating a potential 35.23% downside.
- Geron: Maintains an 'Outperform' rating, with a price target of $6.33 and a potential downside of 86.48%.
Summary of Peer Comparisons
This comparative analysis delivers insights into Agios's standing among its competitors. Here’s a concise breakdown:
- Agios Pharmaceuticals: Consensus - Outperform, Revenue Growth - 28.35%, Gross Profit - $7.12M, ROE - -13.69%
- Veracyte: Consensus - Buy, Revenue Growth - 26.69%, Gross Profit - $77.91M, ROE - 0.51%
- Catalyst Pharmaceuticals: Consensus - Buy, Revenue Growth - 23.23%, Gross Profit - $107.31M, ROE - 6.97%
- Geron: Consensus - Outperform, Revenue Growth - 2941.38%, Gross Profit - $865K, ROE - -20.68%
In terms of revenue growth, Agios ranks lower than its peers, struggling to maintain a competitive position.
Company Overview: Agios Pharmaceuticals
Agios Pharmaceuticals Inc is dedicated to the development of innovative therapies targeting cancer and rare metabolic disorders. The company is fundamentally focused on creating small-molecule medicines with the potential to transform patient treatment. With an emphasis on precision medicine, Agios designs its clinical studies to encompass genetically defined populations.
Financial Health of Agios Pharmaceuticals
The company's market capitalization is lower compared to industry norms, presenting specific challenges. Despite a promising revenue growth rate of 28.35% as of June 30, 2024, Agios's growth trails behind many of its competitors in the healthcare sector.
Net Margin: Currently at a troubling -1115.71%, Agios has some significant challenges to address regarding profitability.
Return on Equity (ROE): The ROE stands at -13.69%, indicating difficulty in achieving adequate returns for shareholders.
Return on Assets (ROA): Similar challenges appear with an ROA at -11.85%. Agios may need to revamp its asset management strategies.
Debt Management: Agios boasts a debt-to-equity ratio of 0.1, showing a conservative stance towards debt financing.
Frequently Asked Questions
1. When will Agios Pharmaceuticals release its earnings report?
The earnings report is scheduled to be released on October 31, 2024.
2. What is the expected EPS for Agios Pharmaceuticals?
Analysts predict an EPS of $-1.01 for the upcoming earnings report.
3. How did Agios perform in the previous quarter?
In the last quarter, Agios missed EPS estimates by $0.10, resulting in a 1.21% drop in share price.
4. What do analysts think about Agios Pharmaceuticals?
Analysts hold a consensus 'Outperform' rating, with a price target suggesting potential upside.
5. How does Agios compare to its peers?
Agios ranks lower in revenue growth and profit margins compared to competitors like Veracyte and Catalyst Pharmaceuticals.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
